Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Renal impairment in type 2 diabetes limits available glucose-lowering treatment options. This trial was conducted to establish the efficacy and safety of liraglutide as an add-on to existing glucose-lowering medications in patients with inadequately controlled type 2 diabetes and moderate renal impairment. RESEARCH DESIGN AND METHODS: In this 26-week, double-blind trial, 279 patients with HbA1c 7–10%, BMI 20–45 kg/m2, and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2; MDRD) were randomized (1:1) to once-daily liraglutide 1.8 mg (n = 140) or placebo (n = 139). RESULTS: The estimated treatment difference in HbA1c from baseline to week 26 was −0.66% (−7.25 mmol/mol) (95% CI −0.90 to −0.43 [−9.82 to −4.69]), P < 0.0001). Fasting plasma glucose decreased more with liraglutide (−1.22 mmol/L [−22.0 mg/dL]) than with placebo (−0.57 mmol/L [−10.3 mg/dL], P = 0.036). There was a greater reduction in body weight with liraglutide (−2.41 kg) than with placebo (−1.09 kg, P = 0.0052). No changes in renal function were observed (eGFR relative ratio to baseline: −1% liraglutide, +1% placebo; estimated treatment ratio [ETR] 0.98, P = 0.36). The most common adverse events were gastrointestinal (GI) adverse effects (liraglutide, 35.7%; placebo, 17.5%). No difference in hypoglycemic episodes was observed between treatment groups (event rate/100 patient-years of exposure: liraglutide, 30.47; placebo, 40.08; P = 0.54). The estimated ratio to baseline for lipase was 1.33 for liraglutide and 0.97 for placebo (ETR 1.37, P < 0.0001). CONCLUSIONS: Liraglutide did not affect renal function and demonstrated better glycemic control, with no increase in hypoglycemia risk but with higher withdrawals due to GI adverse events than placebo in patients with type 2 diabetes and moderate renal impairment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike the LEADER and SCALE trials, in the LIRA-RENAL trial liraglutide was found to be ineffective in improving renal outcomes in a sample of 279 diabetic patients with moderate CKD (eGFR 30–59 mL/min/1.73 m2).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
In the citing paper
“The authors found no difference in terms of eGFR and UACR compared with placebo after 26 weeks of treatment [44].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
Citations
Cites
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725 · cited 1×
“Safety assessments included adverse events (AEs), change from baseline to Week 26 in renal function (eGFR [MDRD] (19), urinary albumin:creatinine ratio [UACR]), amylase, lipase and pulse rate.”
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 1×
“Albuminuria is not only a marker for kidney damage but it is also a cardiovascular risk factor (33,34).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Research works printed but not linked: 1
- Scott, 2014, Efficacy and safety of liraglutide versus placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial (Abstract), J Am Soc Nephrol, 25, 75A
Cited by
Items 201–234 of 234
Improving Drug Use and Dosing in Chronic Kidney Disease
Peter, W. L. S., Wazny, L. D., & Hudson, J. Q. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00017-3
Diabetic Pharmacotherapies in Kidney Disease
Chon, D. A., Oxman, R. T., MULLUR, R. S., & Weinreb, J. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_5
Brief Review of Newer Antiglycemic Agents as Options in the Treatment of Diabetic Kidney Disease
Irons, B. K., Minze, M. G., Lisa, C., & McMurry Michael, E. (2020) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000041
Mácsai, E. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.15
A year in diabetic nephropathy
Tsoutsouki, J., & Chowdhury, T. A. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.293
Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
Kuriyama, S., & Matsumoto, K. (2022) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.53.6_249
New Antidiabetic Agents: Relevance to Cardiovascular Outcomes
Kreutz, R. H., & Algharably, E. A. E. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_20
Évolution de la stratégie thérapeutique hors insuline dans le diabète de type 2
Vatier, C., & Bourcigaux, N. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.03.010 · Cited by 3
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Pascutti, P. F. G., Lorenzo, V. T. D., Oliveira, S. D. A., Oliveira, P. R. P. F. D., Oliveira, I. C. F. D., Pizzolatto, C. A., Machado, N. T. D. C., Rocha, Y. L. N., Batista, A. C. R. D. C., Eismann, F. C. P., et al. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n3-058
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Strategies for Glycemic Management in Patients with Renal Insufficiency
施, 庆. (2023) · Traditional Chinese Medicine · doi:10.12677/tcm.2023.129384
de Souza, L. L. P., Higa, K. C., Costa, I. M., Barreto, A. J. N., & Matos, I. M. (2023) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2023v5n5p112-128
Demidova, T. Y., Titova, V. V., & Izmaylova, M. Y. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202425
Inoue, H., Asahara, S., Nakamura, F., & Kido, Y. (2024) · PubMed Central · doi:10.24546/0100489395
O emergente uso do Ozempic® no tratamento da obesidade
de Maria, E. D. O., Pereira, L. S. S., Felacio, M. D. S., & Shillo, R. S. I. (2024) · Research Society and Development · doi:10.33448/rsd-v13i6.46063
Kleibert, M., Mrozikiewicz‐Rakowska, B., Korycka, K., Płachta, I., Bąk, P. M., Bałut, D., Zieliński, J., & Zgliczyński, W. (2024) · Wiadomości Lekarskie · doi:10.36740/wlek202407103
Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y., Sattar, N. A., Dalakoti, M., et al. (2025) · doi:10.2337/figshare.27890331.v1
C-peptide and epicardial adipose tissue in dialysis-dependent chronic kidney disease patients
D’Marco, L., Checa-Ros, A., Locascio, A., Okojie, O. J., Viejo-Boyano, I., Bermúdez, V., Karohl, C., & Raggi, P. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1650859
Kempf, K., Röhling, M., & Martin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1644442 · Cited by 1
Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J., Wen, Y., Liu, H., Ye, H., Wang, J., & Wang, L. (2024) · Figshare · doi:10.6084/m9.figshare.26606593
Embryotoxic and Oxidative Impact of Dapagliflozin: A Dose‐Dependent Study Using a Chick Embryo Model
Malik, F., Perveen, S., Haider, I., Kanwal, S., Qadeer, I., Abbas, A. O., Hassanien, H. A., Mansour, A. T., Ashour, M., & Shawky, M. (2026) · Journal of Applied Toxicology · doi:10.1002/jat.70073
“Additionally, its use requires careful monitoring in patients with existing kidney issues due to the renal elimination pathway (Davies et al. 2016).”
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Mohammadi, D., Sadeghirad, B., Rasouli, M. A., Saed, L., Baradaran, H. R., & Moradi, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02226-9
Alotaibi, R. R., Alharbi, L. N., Albash, A., Dumlu, G. Y., Alahmadi, R., Alharbi, A. F., Alhassan, R. A., Alkarri, M. N., Farj, T. E., Haqwi, M. F., et al. (2026) · Journal of Advanced Trends in Medical Research · doi:10.4103/atmr.atmr_146_25
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“Liraglutide in the SCALE Diabetes trial statistically significantly reduced UAE compared to placebo [82].”
Hu, H., Hou, S., Chen, W., & Hu, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118405
ภาวะอ้วนและโรคไต: กลไกและการรักษาใหม่
ศุภศิลป์, ฐ., & สถิระพจน์, บ. (2026) · Journal of the Nephrology Society of Thailand · doi:10.63555/jnst.2026.289162
Ajjan, R., Battelino, T., Cos, X., Prato, S. D., Mathieu, C., Almehthel, M. S., Seufert, J., Guerci, B., & Seidu, S. (2026) · The Lancet Primary Care · doi:10.1016/j.lanprc.2026.100193
Kong, A. P. S., Chun Kwan, O., Lai, S., Wang, C.-Y., & Chan, J. C. N. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.08.005
Zhong, Q., Yang, A. L., & Volic, I. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00999-4
Liraglutide reduces lipid accumulation in human orbital fibroblasts in Graves’ orbitopathy
Shih, C.-W., Shih, S.-R., Wei, Y.-H., LIN, C.-H., Shu-Lang, L., Chou, T.-A., Chu, I., Chen, H.-J., Liao, N.-L., & Tsai, F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1914378
Metadata
- Authors
- Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E.
- Affiliations
- University of Leicester (GB)
- Swansea University (GB)
- Weill Cornell Medical College in Qatar (QA)
- Steno Diabetes Center, Gentofte, Denmark
- Clinical Research Development Associates, Rosedale, NY
- Department of Diabetic Nephropathy, Endocrinology Research Centre, Moscow, Russia
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Emory University (US)
- Corresponding author
- Davies, Melanie J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-12-17
- Volume
- 39
- Issue
- 2
- Pages
- 222-230
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2236659707
- Cited by
- 235
- References
- 35
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 17 · 2023: 28 · 2022: 18 · 2021: 19 · 2020: 24 · 2019: 22 · 2018: 28 · 2017: 24 · 2016: 16
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, type 2 diabetes, renal dysfunction, glycemic control, HbA1c, fasting blood glucose, weight loss, renal function, lipase, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Gastrointestinal Tract, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.